ABVX · Abivax S.A.
$120.56
+1.62 (+1.36%)
At close · Aug 19
Market Cap
$10.38B
Shares
87.25M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$120.56
Open$120.43
Day$119.08–121.04
52W close$68.96–145.31
Avg vol 30d911K
Short int5.2M · 6.0% float · 5.1d
Short vol60%
Last earningsDec 31, 2023
DataOct 2023–Aug 2026
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.64
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+1%
above
Price vs 50-day avg
−1%
below
RSI (14)
44
neutral
MACD trend
Negative
52-week position
68%
mid-range
Momentum
relative strength
1-month return
−7%
trailing
6-month return
+1%
trailing
YTD return
−11%
this year
Relative strength
−10%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $121 › 200d $119 — 50d above 200d
Institutional flow
Accumulating
+21% holders QoQ · +96 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
5.95% of float · ▲ +29.3% MoM · 5.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
307 holders — near 2-yr high, broad support
Squeeze score
80
high risk · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
85%
annualized · 1-yr
Max drawdown
−50%
past year
ATR
4.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+1%
Bullish
Price vs 50-day avg
−1%
Neutral
RSI (14)
44
Neutral
MACD trend
Negative
Bearish
52-week position
68%
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $121 › 200d $119 — 50d above 200d
Institutional flow
Accumulating
+21% holders QoQ · +96 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
5.95% of float · ▲ +29.3% MoM · 5.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
307 holders — near 2-yr high, broad support
Price context
position in its 52-week range
Range low $69
Now $121 · 68%
Range high $145
vs 200-day avg +1%
vs 50-day avg -1%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ABVX
this stock
Abivax S.A.
|
$10.38B | -10.6% | — | — | 6.0% |
|
ONC
BeOne Medicines Ltd.
|
$535.83B | +21.5% | +22179.2% | 823.9 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.88B | +16.5% | +46.2% | 30.8 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$84.27B | +5.0% | +20.8% | 20.3 | 3.3% |
|
ARGX
Argenx SE
|
$61.75B | +22.8% | — | — | 2.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ABVX | -4.0% | -7.1% | +0.9% | -3.5% | -10.6% |
| SPY | -0.4% | +2.6% | +10.7% | +2.7% | +12.5% |
| vs SPY | -3.6% | -9.6% | -9.8% | -6.2% | -23.1% |
Key facts
CIK
1956827
CUSIP
00370M103
13F (30d)
287 filings
284 filers
Visit website
Investor relations